Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biot...
Tiziana Life Sciences is a dual-listed (NASDAQ:...
Audentes Therapeutics is a leading AAV-based genetic medicines company focused on ...
Audentes Therapeutics is a leading AAV-based ge...
Ansell Limited provides health and safety protection solutions. The Company has op...
Ansell Limited provides health and safety prote...
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug p...
Enlivex is a clinical stage immunotherapy compa...
Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by expert...
Edesa Biotech Inc. is a clinical-stage biopharm...
Scholar Rock is a biopharmaceutical company focused on the discovery and developme...
Scholar Rock is a biopharmaceutical company foc...
Cancer is one of the most difficult diseases to treat. It is constantly changing, ...
Cancer is one of the most difficult diseases to...
Join the National Investor Network and get the latest information with your interests in mind.